NCT02939274: An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer

NCT02939274
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Skin
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT02939274

Comments are closed.

Up ↑